Lingshi Tan – Founder, Chairman and CEO, dMed, China

Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish dMed; the mission of dMed as ‘more than a CRO’ to support the growth of the Chinese biotech industry; their clinical development capabilities and how they are a partner of choice not only for Chinese companies looking to go global but also global companies looking to come to China; and his insights into current challenges and opportunities of the Chinese clinical development ecosystem.  
When people talk about R&D, it conjures up the common image of drug breakthroughs miraculously emerging from laboratories. However, so much of the heavy lifting comes after that, during the clinical phase
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report